VenBio related stories
All articles and analysis
venBio raises $528m for fifth fundvenBio Fund V will invest in life science companies.
Neurogastrx rakes in $60m Series BNeurogastrx, a developer of treatments for gastrointestinal disorders, has secured $60 million in Series B funding.
VenBio raises about $550m for fourth fundVenBio has closed its fourth life sciences venture fund at about $550 million.
Less pain more gain: venBio and other VCs make great returns on migraine drugsBiotech VCs have played a crucial role in developing medicines for the disorder before selling them to big pharma, and they've realized exceptional returns while making a difference in patients' lives.
- VC-backed Metacrine goes public
San Diego-based Metacrine, a developer of therapies for patients with liver, gastrointestinal and metabolic diseases, has raised about $85 million for its IPO after pricing its 6.54 million shares at $13 per share.
Much more than covid-19 is behind the biotech boomAppetite for biopharma is on the rise as investors want to back scientific advances and the recession-proof sector, and generalist VCs don’t want to miss out on potential outsized returns.
- NFlection Therapeutics nabs $20m Series A
NFlection Therapeutics, Inc., a biopharma therapeutics developer, has raised $20 million in Series A financing.
Four biotech VCs raise new funds amid pandemicAmid the covid-19 outbreak, four biotech funds closed on $3.8 billion in over a week and a half.
- VenBio Partners wraps up third fund at about $394m
VenBio Partners LLC has closed its third life sciences venture fund at about $394 million.
